China Liver Metastases Patient Registry Collecting Clinical Data for Research on Metastatic Liver Cancer Treatments and Outcomes

What this Trial Is About

Researchers are creating a large, standardized clinical registry for patients with metastatic liver cancer. This study, led by the Department of Hepatobiliary Surgery at the University of Science and Technology of China and supported by multiple centers nationwide, aims to collect detailed information on patient characteristics, primary tumors, systemic therapies, and local treatments. The goal is to better understand disease patterns and prognostic factors for secondary liver cancers and to support real-world clinical research. This is an observational registry study where patients receive standard care for metastatic liver cancer based on current guidelines and physician decisions. Treatments may include surgery hepatectomy, ablation, transarterial chemoembolization TACE, systemic chemotherapy, targeted therapy, or immunotherapy. No specific experimental intervention is assigned by investigators, as the registry evaluates standard clinical management in routine practice. Participants will provide baseline clinical data and be followed over time, with outcomes including overall survival up to 10 years, progression-free survival, and treatment-related adverse events within 90 days after treatment. This long-term data collection will help researchers assess real-world outcomes and safety. Participation involves standard clinical care and data collection, with no additional procedures required beyond usual treatment.

China Metastatic Liver Cancer Clinical Registry Cohort Database